Halozyme Therapeutics | HALO - Vermögenswerte

Aktienkurs
62.99
Täglich Wechseln
-0.44 -0.69%
Monatlich
-10.47%
Jährlich
-1.61%
Q1 Prognose
61.53




Vermögenswerte Veränderung Datum
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amarin USD 670.78M 10.96M 2025-12
Amgen USD 90.59B 445M 2025-12
Baxter International USD 20.06B 1.01B 2025-12
Cara Therapeutics USD 43.75M 4.8M 2025-06
Cytokinetics USD 1.42B 12.02M 2025-12
DBV Technologies USD 110.49M 32.93M 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Intrexon USD 73.16M 77.88M 2024-06
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
MannKind USD 792.18M 297.54M 2025-12
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Pfizer USD 208.73B 2.64B 2025-09
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
United Therapeutics USD 7.88B 528.9M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12